Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
At the 2021 American Society of Hematology Annual Meeting, Thomas G. Martin, MD, associate director of the Myeloma Program at the University of California San Francisco, discussed the follow-up results of the CARTITUDE-1 study (NCT03548207) that investigated the use of ciltacabtagene autoleucel (cilta-cel) on progression-free survival (PFS) rates in patients with heavily pretreated multiple myeloma.
At ASH 2021, we presented data from the CARTITUDE-1 study after 2 years of follow-up. This is now a very important timeline because all prior CAR T-cell therapies essentially [produced] a median PFS that was certainly less than 2 years. This [study] was in relapsed or refractory myeloma and in a very heavily pretreated population with 88% of [patients] being triple-class refractory and having 6 or more median lines of therapy. At the 2-year mark, the stringent complete response [CR] rate has gone up quite a bit now at 83%. That goes up over time because the myeloma protein does wane as you [conduct] further follow-up. What we’re going to show is that the PFS rate at 2 years is 61%. The median PFS at 2 years was not reached, which is amazing. If you take the subset of patients in stringent CR, which is 83%, the PFS rate at 2 years is 71% and the overall survival rate is 74% at 2 years of follow up.
Martin T, Usmani S, Berdeja J, et al. Updated results from CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Presented at: 63rd American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021; Atlanta, GA. Abstract 549. Accessed December 2, 2021. https://bit.ly/3dchVj1